Consequently, the use of FAK inhibitors such as GSK2256098 and defactinib (VS-6063) in clinical trials—either as monotherapy or in combination with immunotherapies—likely functions by disrupting tumor–microenvironment interactions that are critical for survival but do not inherently “awaken” dormant cells. This evidence concerns the gene PTK2 and neoplasm.